{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:16:26Z","timestamp":1790972186281,"version":"4.1.0"},"reference-count":33,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2004,4,30]],"date-time":"2004-04-30T00:00:00Z","timestamp":1083283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovasc electrophysiol"],"published-print":{"date-parts":[[2004,5]]},"abstract":"<jats:p> <jats:italic>Introduction:<\/jats:italic> During atrial fibrillation (AF), there is fractionation of extracellular potentials due to head\u2010to\u2010tail interaction and slow conduction of fibrillation waves. We hypothesized that slowing of the rate of AF by infusion of a Class I drug would increase the degree of organization of AF.<\/jats:p><jats:p> <jats:italic>Methods and Results:<\/jats:italic> Seven goats were instrumented with 83 epicardial electrodes on the left atrium, left atrial appendage, Bachmann's bundle, right atrium, and right atrial appendage. AF was induced and maintained by an automatic atrial fibrillator. After AF had persisted for 4 weeks, the Class IC drug cibenzoline was infused at a rate of 0.1 mg\/kg\/min. AF cycle length (AFCL), the percentage of fractionated potentials, conduction velocity (CV), and direction of propagation of the fibrillation waves were measured during baseline, after AFCL was increased by 20, 40, 60, and 80 ms, and shortly before cardioversion. Infusion of cibenzoline increased the mean of the median AFCLs from 96 \u00b1 6 ms to 207 \u00b1 43 ms (P &lt; 0.0001). The temporal variation in AFCL in different parts of the atria was 8% to 20% during control and, with the exception of Bachmann's bundle, was not significantly reduced during cibenzoline infusion. CV decreased from 76 \u00b1 14 ms to 52 \u00b1 9 cm\/s (P &lt; 0.01). Cibenzoline increased the percentage of single potentials from 81%\u00b1 4% to 91%\u00b1 4% (P &lt; 0.01) and decreased the incidence of double potentials from 14%\u00b1 4% to 7 \u00b1 5% (P &lt; 0.01) and multiple potentials from 5%\u00b1% to 1%\u00b1 2% (P &lt; 0.001). Whereas during control, linking (consecutive waves propagating in the same direction) during seven or more beats occurred in 9%\u00b1 15% of the cycles, after cibenzoline the degree of linking had increased to 40%\u00b1 33% (P &lt; 0.05). During the last two beats before cardioversion, there was a sudden prolongation in AFCL from 209 \u00b1 37 ms to 284 \u00b1 92 ms (P &lt; 0.01) and a strong reduction in fractionated potentials (from 22%\u00b1 12% to 6%\u00b1 5%, P &lt; 0.05).<\/jats:p><jats:p> <jats:italic>Conclusion:<\/jats:italic> The Class IC drug cibenzoline causes a decrease in fractionation of fibrillation electrograms and an increase in the degree of linking during AF. This supports the observation that Class I drugs widen the excitable gap during AF. <jats:italic>(J Cardiovasc Electrophysiol, Vol. 15, pp. 572\u2010580, May 2004)<\/jats:italic><\/jats:p>","DOI":"10.1046\/j.1540-8167.2004.03402.x","type":"journal-article","created":{"date-parts":[[2010,8,16]],"date-time":"2010-08-16T09:32:46Z","timestamp":1281951166000},"page":"572-580","source":"Crossref","is-referenced-by-count":38,"title":["Fractionation of Electrograms and Linking of Activation During Pharmacologic Cardioversion of Persistent Atrial Fibrillation in the Goat"],"prefix":"10.1111","volume":"15","author":[{"given":"ZHAOLIANG","family":"SHAN","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PEPIJN H.","family":"VAN DER VOORT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YURI","family":"BLAAUW","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MATTIAS","family":"DUYTSCHAEVER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MAURITS A.","family":"ALLESSIE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,4,30]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(59)90274-1"},{"key":"e_1_2_5_3_2","first-page":"265","volume-title":"Cardiac Electrophysiology and Arrhythmias","author":"Allessie MA","year":"1985"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.89.4.1665"},{"key":"e_1_2_5_5_2","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1161\/01.CIR.95.2.511","article-title":"Simultaneous multisite mapping studies during induced atrial fibrillation in the sterile pericarditis model: insight into the mechanism of its maintenance","volume":"95","author":"Kumagai K","year":"1997","journal-title":"Circulation"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8159.1996.tb03269.x"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8159.1978.tb03504.x"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.58.3.356"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.92.6.1619"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(95)00612-5"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.2.260"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.71.2.271"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(95)90845-F"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/14.2.267"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.91.8.2245"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.86.2.375"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.92.7.1954"},{"key":"e_1_2_5_18_2","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1161\/circ.104.17.2118","article-title":"ACC\/AHA\/ESC guidelines for the management of patients with atrial fibrillation: Executive summary: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation): Developed in collaboration with the North American Society of Pacing and Electrophysiology","volume":"104","author":"Fuster V","year":"2001","journal-title":"Circulation"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199108000-00016"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(96)00216-7"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1540-8167.2001.01010.x"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.98.16.1688"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.100.6.666"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1098\/rspa.1992.0084"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.75.6.1014"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1540-8167.2002.01264.x"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(98)00506-8"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8167.1998.tb01836.x"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8167.1998.tb00940.x"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(02)00251-1"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8159.1998.tb01058.x"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.22.3.363"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8167.1997.tb00813.x"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.eurheartj.a062553"}],"container-title":["Journal of Cardiovascular Electrophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1540-8167.2004.03402.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1540-8167.2004.03402.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T06:20:48Z","timestamp":1694413248000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1540-8167.2004.03402.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4,30]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["10.1046\/j.1540-8167.2004.03402.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1540-8167.2004.03402.x","archive":["Portico"],"relation":{},"ISSN":["1045-3873","1540-8167"],"issn-type":[{"value":"1045-3873","type":"print"},{"value":"1540-8167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,4,30]]}}}